Page 7 - Biocon

Sensex ends at day's low, down 746 pts ; Bajaj Auto jumps 11%; RIL down 2%

Shares of Reliance Industries ended 2.4 per cent lower on Friday ahead of the announcement of its December quarter results. The shares have surged around 6 per cent during the week

Market reacts negatively to Biocon's weaker results, exit of biologics' MD

Analysts have raised doubts over the $1 billion guidance for biosimilars by FY22 and Hamacher's exit due to "professional differences"

Biocon tanks 10% on lower-than-expected December quarter results

Due to professional differences with the chairperson on strategic priorities and the vision for the company, Dr Christiane Hamacher has stepped down as the MD of Biocon Biologics

Stocks to watch: RIL, YES Bank, Vedanta, HDFC Bank, SBI Card, Biocon

SBI Cards and Payment Services reported nearly 52 per cent dip in its net profit to Rs 210 crore in the third quarter ended December 2020

Biocon posts 19% dip in Q3 net profit as generics biz takes a hit

Biocon's consolidated revenue for Q3 of FY21 increased by 7.20 per cent at Rs 1878.9 crore as against Rs 1752.6 crore for the said quarter last year

Pharma, healthcare growing, but they face challenges beyond Covid-19

These sectors will face another tough year after coronavirus pandemic, the first challenge being vaccination of India's 1.3 billion people. Devangshu Datta explains the opportunities and threats

Biocon gains 2% after arm gets Rs 555 crore capital injection from ADQ

ADQ will invest Rs 555 Crore for a 1.80 per cent minority stake in the biosimilar business, valuing Biocon Biologics at a post money valuation of around $4.17 billion

Stocks to watch: TCS, Biocon, Bharat Rasayan, Vodafone Idea, Tata Power

Biocon announced that its subsidiary Biocon Biologics has approved a primary equity investment by Abu Dhabi-based ADQ, one of the region's largest holding companies

Biocon Biologics gets capital injection of $150 mn from Goldman Sachs

Transaction values the IPO-bound biologics arm of Biocon at $3.94 billion

Biocon: Street to keep an eye on CY21 launches, market share gains

Launch of a cancer drug was delayed due to Covid-19

Nifty outlook and stock recommendations by Sameet Chavan of Angel Broking

If Nifty again slide below 13,626, we may see some corrective move in the concluding week of the current calendar year

USFDA informs Biocon, Mylan of deferred action on biosimilar license plea

Biocon said its arm, Biocon Biologics, and Mylan have been informed by the USFDA of a deferred action on the biologics license application for a biosimilar to drug Avastin

Hopefully DCGI to give nod for Oxford's vaccine immediately: Biocon chief

India saw 37,975 new coronavirus infections in a day taking the country's Covid-19 caseload to 91.77 lakh

Biocon posts 22% fall in Q2 net profit on high R&D expenses, staff costs

The Bengaluru-headquartered company posted 10 per cent growth in consolidated revenue on a y-o-y basis to Rs 1,760 crore in Q2

Strong prospects of Biologics business keep Street positive on Biocon

Even though Q2 performance missed estimates, analysts expect a stronger second half

Sebi levies fine on Biocon employee for violating insider trading norms

Accordingly, Sebi imposed a consolidated fine of Rs 3 lakh on Singh for both the violations -- not obtaining pre-clearance and making delayed disclosures

India has potential to increase Covid testing 10-fold: Kiran Mazumdar-Shaw

India, which in March imposed the largest nationwide lockdown globally in response to the pandemic, was taken by surprise by the surging number of infections when it started removing the restrictions

Forbes India Rich List 2020: Ambani dominance continues; see full list

With a global health crisis raging, listed pharma entrepreneurs fared well while those with interests in real estate suffered

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

With phase 4 clinical trials now on, the sales may see a further uptick if data supports its use on Covid-19 patients, said experts.

Biocon set for bigger insulin play, aims to reach one in five diabetics

Biocon Biologics CEO says portfolio to form a substantial part of $1 bn revenue target, to roll out insulin Aspart by next year